Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICURE: PIPAC in High-risk Gastric Cancer
NCT06295094Phase 2Not yet recruiting
- Sponsor
- University Hospital Odense
- Start
- Sep 2024
- Primary completion
- Jan 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
A Phase 2 trial of cisplatin, doxorubicin in gastric adenocarcinoma, sponsored by University Hospital Odense. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
cisplatindoxorubicin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT06295094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295094.